The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Teratoma formation by human embryonic stem cells: Evaluation of essential parameters for future safety studies
Open accessAbstract
Transplantation of human embryonic stem cells (hESC) into immune-deficient mice leads to the formation of differentiated tumors comprising all three germ layers, resembling spontaneous human teratomas. Teratoma assays are considered the gold standard for demonstrating differentiation potential of pluripotent hESC and hold promise as a standard for assessing safety among hESC-derived cell populations intended for therapeutic applications. We tested the potency of teratoma formation in seven anatomical transplantation locations (kidney capsule, muscle, subcutaneous space, peritoneal cavity, testis, liver, epididymal fat pad) in SCID mice with and without addition of Matrigel, and found that intramuscular teratoma formation was the most experimentally convenient, reproducible, and quantifiable. In the same experimental setting, we compared undifferentiated hESC and differentiated populations enriched for either beating cardiomyocytes or definitive endoderm derivatives (insulin-secreting beta cells), and showed that all cell preparations rapidly formed teratomas with varying percentages of mesoderm, ectoderm, and endoderm. In limiting dilution experiments, we found that as little as two hESC colonies spiked into feeder fibroblasts produced a teratoma, while a more rigorous single-cell titration achieved a detection limit of 1/4000. In summary, we established core parameters essential for facilitating safety profiling of hESC-derived products for future therapeutic applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Embryonic Stem Cell Lines Derived from Human Blastocysts
Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A., Swiergiel, J. J., Marshall, V. S., & Jones, J. M. (1998) · Science · doi:10.1126/science.282.5391.1145 · Cited by 15,926
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310 · cited 1×
“For example, amniotic stem cell lines were recently shown to exhibit incomplete pluripotency, while human-induced pluripotent stem (iPS) cells readily formed bona fide teratomas in SCID mice (De Coppi et al., 2007; Takahashi et al., 2007; Yu et al., 2007).”
Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro
Reubinoff, B. E., Pera, M. F., Fong, C.-Y., Trounson, A., & Bongso, A. (2000) · Nature Biotechnology · doi:10.1038/74447 · Cited by 2,706
In vitro differentiation of transplantable neural precursors from human embryonic stem cells
Zhang, S.-C., Wernig, M., Duncan, I. D., Brüstle, O., & Thomson, J. A. (2001) · Nature Biotechnology · doi:10.1038/nbt1201-1129 · Cited by 1,912
Isolation of amniotic stem cell lines with potential for therapy
De Coppi, P., Bartsch, G., Siddiqui, M. M., Xu, T., Santos, C. C., Perin, L., Mostoslavsky, G., Serre, A. C., Snyder, E. Y., Yoo, J. J., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1274 · Cited by 1,869
Kroon, E., Martinson, L. A., Kadoya, K., Bang, A. G., Kelly, O. G., Eliazer, S., Young, H., Richardson, M., Smart, N. G., Cunningham, J., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1393 · Cited by 1,843 · cited 6×
“display bona fide teratoma histology (Eshpeter et al. 2008; Kroon et al., 2008), similar to outgrowths described in our own previous work (Phillips et al.”
InfluentialEfficient tumour formation by single human melanoma cells
Quintana, E., Shackleton, M., Sabel, M. S., Fullen, D. R., Johnson, T. M., & Morrison, S. J. (2008) · Nature · doi:10.1038/nature07567 · Cited by 1,796
Embryonic stem cell differentiation: emergence of a new era in biology and medicine
Keller, G. (2005) · Genes & Development · doi:10.1101/gad.1303605 · Cited by 1,151
Neural progenitors from human embryonic stem cells
Reubinoff, B. E., Itsykson, P., Turetsky, T., Pera, M. F., Reinhartz, E., Itzik, A., & Ben-Hur, T. (2001) · Nature Biotechnology · doi:10.1038/nbt1201-1134 · Cited by 1,119
Cited by
Embryonic stem cell trials for macular degeneration: a preliminary report
Schwartz, S. D., Hubschman, J.-P., Heilwell, G., Franco-Cardenas, V., Pan, C. K., Ostrick, R. M., Mickunas, E., Gay, R., Klimanskaya, I., & Lanza, R. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60028-2 · Cited by 1,409
Schwartz, S. D., Regillo, C. D., Lam, B. L., Eliott, D., Rosenfeld, P. J., Gregori, N. Z., Hubschman, J.-P., Davis, J. L., Heilwell, G., Spirn, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61376-3 · Cited by 1,327
The tumorigenicity of human embryonic and induced pluripotent stem cells
Ben-David, U., & Benvenisty, N. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3034 · Cited by 889
“In view of reports suggesting that as few as several hundred pluripotent cells are sufficient to generate tumour”
BackgroundDerivation of naïve human embryonic stem cells
Ware, C. B., Nelson, A. M., Mecham, B., Hesson, J., Zhou, W., Jonlin, E. C., Jimenez-Caliani, A. J., Deng, X., Cavanaugh, C., Cook, S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319738111 · Cited by 468
Advances in islet encapsulation technologies
Desai, T., & Shea, L. D. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.232 · Cited by 427
Tang, C., Lee, A. S., Volkmer, J.-P., Sahoo, D., Nag, D., Mosley, A. R., Inlay, M. A., Ardehali, R., Chavez, S. L., Pera, R. R., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1947 · Cited by 375
Quality cell therapy manufacturing by design
Lipsitz, Y. Y., Timmins, N. E., & Zandstra, P. W. (2016) · Nature Biotechnology · doi:10.1038/nbt.3525 · Cited by 311
Ben-David, U., Gan, Q.-F., Golan-Lev, T., Arora, P., Yanuka, O., Oren, Y. S., Leikin-Frenkel, A., Graf, M., Garippa, R., Boehringer, M., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2012.11.015 · Cited by 305
Moradi, S., Mahdizadeh, H., Šarić, T., Kim, J., Harati, J., Shahsavarani, H., Greber, B., & Moore, J. B. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1455-y · Cited by 287
Human haematopoietic stem cell development: from the embryo to the dish
Ivanovs, A., Rybtsov, S., Ng, E. S., Stanley, E. G., Elefanty, A. G., & Medvinsky, A. (2017) · Development · doi:10.1242/dev.134866 · Cited by 279
Scalable expansion of human pluripotent stem cells in suspension culture
Zweigerdt, R., Olmer, R., Singh, H., Haverich, A., & Martin, U. (2011) · Nature Protocols · doi:10.1038/nprot.2011.318 · Cited by 271
An, D., Chiu, A., Flanders, J. A., Song, W., Shou, D., Lu, Y.-C., Grunnet, L. G., Winkel, L., Ingvorsen, C., Christophersen, N. S., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708806115 · Cited by 200
Human pluripotent stem-cell-derived islets ameliorate diabetes in non-human primates
Du, Y., Liang, Z., Wang, S., Sun, D., Wang, X., Liew, S. Y., Lu, S., Wu, S., Jiang, Y., Wang, Y., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01645-7 · Cited by 155
Self-citationWang, X., Maxwell, K. G., Wang, K., Bowers, D. T., Flanders, J. A., Liu, W., Wang, L.-H., Liu, Q., Liu, C., Naji, A., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb4601 · Cited by 119
Fail-Safe System against Potential Tumorigenicity after Transplantation of iPSC Derivatives
Itakura, G., Kawabata, S., Ando, M., Nishiyama, Y., Sugai, K., Ozaki, M., Iida, T., Ookubo, T., Kojima, K., Kashiwagi, R., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.02.003 · Cited by 115
Stem cell therapy in Alzheimer’s disease: possible benefits and limiting drawbacks
Alipour, M., Nabavi, S. M., Arab, L., Vosough, M., Pakdaman, H., Ehsani, E., & Shahpasand, K. (2019) · Molecular Biology Reports · doi:10.1007/s11033-018-4499-7 · Cited by 63
Aghazadeh, Y., Sarangi, F., Poon, F., Nkennor, B., McGaugh, E. C., Nunes, S. S., & Nostro, M. C. (2022) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.03.004 · Cited by 62
“It is noteworthy that previous studies indicated that the in vivo microenvironment can also influence cell fate specification and cell growth, because the same cell population transplanted into different sites developed teratomas with various compositions and at different rates (Hentze et al., 2009; Lawrenz et al., 20…”
BackgroundStrategies to Improve the Safety of iPSC-Derived β Cells for β Cell Replacement in Diabetes
Pellegrini, S., Zamarian, V., & Sordi, V. (2022) · Transplant International · doi:10.3389/ti.2022.10575 · Cited by 38
Mouse Pluripotent Stem Cell Differentiation Under Physiological Oxygen Reduces Residual Teratomas
Millman, J. R., Tan, J. H., & Colton, C. K. (2021) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-021-00687-8 · Cited by 7
Metadata
- Authors
- Hentze, H., Soong, P. L., Wang, S. T., Phillips, B. W., Putti, T. C., & Dunn, N. R.
- Venue
- Stem Cell Research
- Publisher
- Elsevier BV
- Published
- 2009-05
- Volume
- 2
- Issue
- 3
- Pages
- 198-210
- ISSN
- 1873-5061 (ISSN-L)
- OpenAlex
- W2114190644
- Cited by
- 501
- References
- 55
- FWCI
- 9.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.